Scarica l'app Stockscreener
4.81
9.07%
0.40
Dopo l'orario di chiusura:
5.20
0.39
+8.11%
Precedente Chiudi:
$4.41
Aprire:
$4.765
Volume 24 ore:
168.25K
Relative Volume:
0.86
Capitalizzazione di mercato:
$217.87M
Reddito:
$84.82M
Utile/perdita netta:
$-21.43M
Rapporto P/E:
-9.8163
EPS:
-0.49
Flusso di cassa netto:
$-27.23M
1 W Prestazione:
+10.57%
1M Prestazione:
+1.91%
6M Prestazione:
-23.41%
1 anno Prestazione:
-62.45%
Intervallo 1D:
$4.725
$4.85
Intervallo di 1 settimana:
$4.23
$4.85
Portata 52W:
$3.55
$16.11
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Nome
Y Mabs Therapeutics Inc
Settore
Industria
Telefono
646-885-8505
Indirizzo
202 CARNEGIE CENTER, PRINCETON, NY
Confronta YMAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
4.81 | 199.75M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-11-18 | Iniziato | Oppenheimer | Outperform |
| 2024-08-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-28 | Iniziato | Truist | Buy |
| 2023-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-04-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-27 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-12-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-10-31 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-10-31 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-03 | Ripresa | Guggenheim | Buy |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-11-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-23 | Ripresa | Cowen | Outperform |
| 2021-03-22 | Ripresa | JP Morgan | Overweight |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2020-05-01 | Iniziato | Janney | Buy |
| 2020-04-29 | Iniziato | Morgan Stanley | Equal-Weight |
| 2019-12-24 | Iniziato | JP Morgan | Overweight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-04 | Iniziato | Wedbush | Outperform |
| 2019-04-01 | Iniziato | H.C. Wainwright | Buy |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-10-16 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Y Mabs Therapeutics Inc Borsa (YMAB) Ultime notizie
What drives Y mAbs Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
What analysts say about Y mAbs Therapeutics Inc. stockBreakthrough investment results - jammulinksnews.com
How the (YMAB) price action is used to our Advantage - news.stocktradersdaily.com
Is Y mAbs Therapeutics Inc. a good long term investmentMarket-beating performance - jammulinksnews.com
Y mAbs Therapeutics Inc. Stock Analysis and ForecastUnrivaled growth potential - Autocar Professional
Y-Mabs Therapeutics Elects New Director at Annual Meeting - TipRanks
Y-mAbs Therapeutics announces results of annual shareholder meeting votes - Investing.com
What makes Y mAbs Therapeutics Inc. stock price move sharplySafe and Smart Investment Picks - Newser
Why Y mAbs Therapeutics Inc. stock attracts strong analyst attentionFree Risk Assessment Services - Newser
2nd Circ. Affirms Biotech Founder's Win In Trading Suit - Law360
Transcript : Y-mAbs Therapeutics, Inc.Shareholder/Analyst Call - MarketScreener
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
YMAB SEC FilingsY-Mabs Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Is Y-mAbs Therapeutics, Inc. overvalued or undervalued? - MarketsMojo
Cantor Fitzgerald Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Overweight Recommendation - MSN
Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles - Investing.com India
Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles By Investing.com - Investing.com South Africa
Millennium Management LLC Cuts Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 7,765 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate - Yahoo Finance
(YMAB) Long Term Investment Analysis - news.stocktradersdaily.com
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DE - Defense World
BNP Paribas Financial Markets Has $38,000 Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Jane Street Group LLC - Defense World
YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Class Action Pending - ACCESS Newswire
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $179,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Deutsche Bank AG - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at Oppenheimer - Defense World
Y Mabs Therapeutics Inc Azioni (YMAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):